Walma, M. S.
,
Rombouts, S. J.
Brada, L. J. H.
Borel Rinkes, I. H.
Bosscha, K.
Bruijnen, R. C.
Busch, O. R.
Creemers, G. J.
Daams, F.
van Dam, R. M.
van Delden, O. M.
Festen, S.
Ghorbani, P.
de Groot, D. J.
de Groot, J. W. B.
Haj Mohammad, N.
van Hillegersberg, R.
de Hingh, I. H.
D’Hondt, M.
Kerver, E. D.
van Leeuwen, M. S.
Liem, M. S.
van Lienden, K. P.
Los, M.
de Meijer, V. E.
Meijerink, M. R.
Mekenkamp, L. J.
Nio, C. Y.
Oulad Abdennabi, I.
Pando, E.
Patijn, G. A.
Polée, M. B.
Pruijt, J. F.
Roeyen, G.
Ropela, J. A.
Stommel, M. W. J.
de Vos-Geelen, J.
de Vries, J. J.
van der Waal, E. M.
Wessels, F. J.
Wilmink, J. W.
van Santvoort, H. C.
Besselink, M. G.
Molenaar, I. Q.
Funding for this research was provided by:
KWF Kankerbestrijding (2014-7444)
Article History
Received: 14 September 2020
Accepted: 3 April 2021
First Online: 29 April 2021
Declarations
:
: The study is performed in accordance with the Declaration of Helsinki. Furthermore, the study is done in accordance with the Dutch Medical Research Involving Human Subjects Act (WMO) and the 93/42/EEC European Medical Device Directive. The protocol has been approved by the Medical Ethical Committee of the Academic Medical Centre (reference number: 2015_325, 24 December 2014; contact: ExternalRef removed); secondary approval was obtained from all participating centers individually. Patients are only eligible for inclusion after written informed consent. All patient information and informed consent forms are approved by the Institutional Review Board. The trial is registered in the Dutch Trial Registry (ExternalRef removed, Trial ID: NTR 5517) and within ClinicalTrials.gov (NCT03690323).
: Not applicable.
: JWdG has received personal fees outside the submitted work from Bristol-Myers Squibb, Roche, Pierre-Fabre, Servier, MSD, and Novartis. RvH is a proctor for Intuitive, is part of the advisory board of Medtronics, and received an educational grant from Olympus outside the submitted work. IdH reports grants from Roche Pharmaceutical, QPS/RanD, and Medtronic, outside the submitted work. KvL reports personal fees and non-financial support from AngioDynamics, outside the submitted work. VEdM reports grants from Stichting Louise Vehmeijer and NWO and travel grants from Astellas and Neovii, outside the submitted work. MRM reports grants, personal fees, and non-financial support from Angiodynamics; grants and personal fees from Medtronic Covidien; and non-financial support from Cascination, outside the submitted work. NHM reports advisory board fees for her institution from BMS, Eli Lilly, Servier, and MSD. JdVG reports grants and non-financial support from Servier, outside the submitted work. JWW reports research grants from Servier, Halozyme, Novartis, Celgene, Astra Zeneca, Pfizer, Roche, Amgen, and Merck and a consulting/advisory role for Servier and Celgene. HCvS has received a research grant from the Dutch Cancer Society, during and outside the submitted work. MGB has received a research grant from the Dutch Cancer Society, during and outside the conduct of the study. IQM has received a research grant from the Dutch Cancer Society, during the conduct of the study. The other authors declare that they have no competing interests.